Ceramide Signaling Pathway in Neurodegeneration

Migration, Crosslink

📖

Ceramide Signaling Pathway in Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:49 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-ceramide-signaling-neuro

📖 Wiki Page

mechanism2973 wordssynced 2026-04-02

Ceramide Signaling Pathway in Neurodegeneration

Overview

Ceramide, the fundamental building block of sphingolipids, has emerged as a critical signaling molecule in the central nervous system [@hannun2008]. Beyond its structural role in cell membranes, ceramide functions as a potent bioactive lipid that regulates cell death, survival, inflammation, and metabolic processes [@goi2002]. The ceramide signaling pathway has been implicated in the pathogenesis of multiple neurodegenerative diseases, including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), and Huntington's disease [@grsch2012]. Understanding the complex ceramide network provides insight into disease mechanisms and identifies potential therapeutic targets.

Ceramide Biology

Structure and Metabolism

Ceramide (N-acyl-sphingosine) consists of a sphingoid base linked to a fatty acid chain of varying length (typically C14-C26) [@merrill2011]. The diversity in fatty acid chain length and saturation creates a family of ceramides with distinct biological functions. Ceramide serves as the precursor for more complex sphingolipids, including sphingomyelin, glycosphingolipids, and gangliosides.

Key metabolic pathways:

...

Ceramide Signaling Pathway in Neurodegeneration

Overview

Ceramide, the fundamental building block of sphingolipids, has emerged as a critical signaling molecule in the central nervous system [@hannun2008]. Beyond its structural role in cell membranes, ceramide functions as a potent bioactive lipid that regulates cell death, survival, inflammation, and metabolic processes [@goi2002]. The ceramide signaling pathway has been implicated in the pathogenesis of multiple neurodegenerative diseases, including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), and Huntington's disease [@grsch2012]. Understanding the complex ceramide network provides insight into disease mechanisms and identifies potential therapeutic targets.

Ceramide Biology

Structure and Metabolism

Ceramide (N-acyl-sphingosine) consists of a sphingoid base linked to a fatty acid chain of varying length (typically C14-C26) [@merrill2011]. The diversity in fatty acid chain length and saturation creates a family of ceramides with distinct biological functions. Ceramide serves as the precursor for more complex sphingolipids, including sphingomyelin, glycosphingolipids, and gangliosides.

Key metabolic pathways:

De novo synthesis: Ceramide is synthesized in the endoplasmic reticulum through the action of serine palmitoyltransferase (SPT) and ceramide synthase (CerS) [@hanada2003]

Salvage pathway: Ceramidase enzymes regenerate ceramide from sphingosine and free fatty acids [@mao2008]

Hydrolysis: Acid and neutral sphingomyelinases convert sphingomyelin to ceramide [@kono2003]

Ceramide Synthases

Six ceramide synthase isoforms (CerS1-6) with distinct substrate specificities and tissue expression patterns have been identified [@levy2007]:

CerS1: Preferentially produces C18-ceramide, highly expressed in brain
CerS2: Generates C20-C24 ceramides, essential for myelin maintenance
CerS3: Produces very-long-chain ceramides, important for skin barrier
CerS4: Generates C18- and C20-ceramides, expressed in various tissues
CerS5/CerS6: Produce C14- and C16-ceramides, involved in apoptosis

Ceramide Signaling Mechanisms {#ceramide-signaling-mechanisms}

Ceramide Metabolism and Signaling Pathway

Mermaid diagram (expand to render)

Ceramide in Disease-Specific Context

Mermaid diagram (expand to render)

Therapeutic Targeting of Ceramide

Mermaid diagram (expand to render)

Ceramide Signaling Mechanisms

Receptor Interactions

Ceramide can signal through multiple mechanisms:

Direct receptor interaction:

Ceramide binds to specific receptors including CERT (ceramide transfer protein) and PKR (protein kinase R)
Activates phosphatase PP1 and PP2A
Modulates protein kinase C isoforms [@ruvolo2003]

Membrane microdomains:

Ceramide accumulates in lipid rafts, disrupting their organization
Affects receptor clustering and signal transduction
Influences membrane fluidity and protein trafficking [@gulbins2002]

Downstream Effectors

Kinases:

PKC isoforms: Ceramide activates conventional PKC (α, β, γ) and novel PKC (δ, ε)
MAPK pathways: Ceramide induces JNK and p38 activation
Akt/PKB: Ceramide can inhibit Akt signaling through PP2A activation

Phosphatases:

PP1/PP2A: Ceramide directly activates these phosphatases
SHP-1: Ceramide induces tyrosine phosphatase activation

Transcription factors:

NF-κB: Ceramide can both activate and inhibit NF-κB depending on context
AP-1: Ceramide stimulates c-Jun phosphorylation
p53: Ceramide can stabilize p53 and promote apoptosis [@dbaibo2001]

Ceramide in Alzheimer's Disease

Evidence for Altered Ceramide Metabolism

Multiple studies have documented alterations in ceramide levels in AD brains and peripheral tissues. A meta-analysis of 12 studies found significantly increased ceramide levels in AD prefrontal cortex compared to controls, with the most prominent increases in C16- and C18-ceramides [@haughey2010].

Key findings:

Elevated cortical ceramide correlates with cognitive decline [@liu2015]
Increased serum ceramide predicts conversion from MCI to AD [@mielke2015]
Genetic variants in ceramide metabolism genes (SMPD4, SGMS1) associated with AD risk [@wang2015]

Mechanisms in AD Pathogenesis

Amyloidogenesis:

Ceramide increases amyloid precursor protein (APP) expression [@puglielli2003]
Ceramide enhances β-secretase (BACE1) activity [@puglielli2002]
Ceramide promotes amyloid-beta (Aβ) aggregation [@chalfant2002]

Tau pathology:

Ceramide activates GSK3β, promoting tau phosphorylation [@sun2013]
Ceramide induces tau aggregation [@he2011]
Neuroinflammation-driven ceramide accumulation exacerbates tau pathology

Synaptic dysfunction:

Ceramide reduces synaptic plasticity and impairs LTP [@stoica2010]
Alters NMDA receptor function and trafficking [@wang2013]
Promotes dendritic spine loss through ROS production

Neuronal apoptosis:

Ceramide activates both intrinsic and extrinsic apoptotic pathways [@obeid1995]
Mitochondrial ceramide accumulation leads to cytochrome c release
Ceramide-induced ER stress activates CHOP and caspase-12

Ceramide-Amyloid Interplay

Aβ and ceramide mutually reinforce each other. Aβ exposure increases ceramide synthesis in neurons and glia, while ceramide promotes amyloidogenic APP processing [@lee2004]. This creates a positive feedback loop driving disease progression.

Ceramide in Parkinson's Disease

Evidence for Ceramide Alterations

Parkinson's disease is associated with specific changes in ceramide metabolism in the substantia nigra and peripheral tissues. Post-mortem studies show increased C16- and C18-ceramide in the substantia nigra of PD patients [@abbott2014].

Evidence:

Elevated serum ceramide in PD vs. controls [@gonzlezdomnguez2015]
Ceramide correlates with disease severity (UPDRS scores) [@song2017]
CERK (ceramide kinase) variants associated with PD risk [@chen2016]

Mechanisms of Dopaminergic Neuron Loss

Mitochondrial dysfunction:

Ceramide directly inhibits complex I activity [@casamenti2015]
Ceramide promotes mitochondrial permeability transition
Ceramide induces mitophagy dysfunction

Oxidative stress:

Ceramide stimulates ROS production [@giri2006]
Ceramide depletes cellular antioxidant defenses
Ceramide activates NADPH oxidase in microglia

Neuroinflammation:

Ceramide activates microglia [@glass2010]
Ceramide promotes TNF-α and IL-1β production
Ceramide sustains chronic neuroinflammation

Alpha-synuclein interaction:

Ceramide promotes α-synuclein aggregation [@sharon2003]
Ceramide enhances α-synuclein secretion
Ceramide may facilitate prion-like propagation

Ceramide in Amyotrophic Lateral Sclerosis

Ceramide Alterations in ALS

ALS is associated with specific ceramide metabolism changes. Elevated ceramide has been documented in ALS patient spinal cord tissue and CSF [@cutler2002].

Key findings:

C18-ceramide significantly elevated in ALS motor cortex [@van2007]
Ceramide correlates with disease progression rate [@garde2017]
Genetic variants in SMPD1 associated with ALS risk [@lill2012]

Mechanisms in Motor Neuron Degeneration

Excitotoxicity:

Ceramide enhances glutamate-induced toxicity [@fenger2016]
Ceramide alters AMPA receptor trafficking
Ceramide disrupts astrocytic glutamate uptake

Mitochondrial dysfunction:

Ceramide directly induces motor neuron mitochondrial damage [@liu2016]
Ceramide promotes mitochondrial fragmentation
Ceramide activates parkin-dependent mitophagy

Protein aggregation:

Ceramide promotes TDP-43 mislocalization [@zhang2018]
Ceramide may interact with mutant SOD1
Ceramide disrupts proteostasis pathways

Ceramide in Multiple Sclerosis

Demyelination and Ceramide

Multiple sclerosis features prominent ceramide accumulation in demyelinating lesions. Ceramide accumulation contributes to oligodendrocyte death and impaired remyelination [@shin2017].

Evidence:

Elevated ceramide in MS white matter lesions [@schmitt2005]
Ceramide toxicity to oligodendrocytes demonstrated in vitro [@bakhti2014]
Ceramide synthase inhibitors promote remyelination [@vautier2015]

Ceramide in Huntington's Disease

Ceramide Alterations in HD

Huntington's disease is associated with increased ceramide in the striatum and cortex. Mutant huntingtin disrupts ceramide metabolism through multiple mechanisms [@geraud2015].

Key findings:

HTT mutation alters ceramide synthase activity [@abi2014]
Elevated C18-ceramide in HD brain [@zhang2014]
Ceramide contributes to transcriptional dysregulation

Therapeutic Targeting of Ceramide

Current Approaches

| Agent | Target | Status | Disease |
|-------|--------|--------|---------|
| Fingolimod (FTY720) | S1P receptor, ceramide modulation | Approved for MS | MS |
| Myriocin | Serine palmitoyltransferase | Preclinical | AD, PD |
| L-cycloserine | Ceramide synthase | Preclinical | PD |
| PPPP | PP1/PP2A inhibition | Preclinical | AD |

Challenges in Ceramide-Targeted Therapy

Pleiotropic effects: Ceramide has both pro-survival and pro-death functions

Isoform specificity: Different CerS produce different ceramide species

Cell-type specificity: Effects differ in neurons vs. glia

Temporal considerations: Optimal intervention timing unclear

BBB penetration: Many small molecules don't cross

Emerging Strategies

Selective CerS modulators: Target specific ceramide synthase isoforms
Ceramide analogs: Synthetic ceramides with modified activity
Enzyme inhibitors: Target specific metabolic enzymes
Gene therapy: Modulate ceramide metabolism genes
Combination approaches: Target ceramide + other pathways

Ceramide in Glial Cells

Microglial Activation

Ceramide is a potent activator of microglia. Microglial ceramide production creates a self-reinforcing inflammatory loop [@liu2016a]:

Initial trigger (Aβ, α-synuclein, damage signals) activates microglia

Microglia produce ceramide and other lipids

Ceramide acts on neurons and glia to promote inflammation

Chronic activation leads to sustained neuroinflammation

Astrocyte Interactions

Ceramide modulates astrocyte function:

Induces inflammatory mediator expression
Alters astrocyte metabolism
Promotes reactive astrocytosis
Disrupts astrocyte-neuron metabolic coupling

Cross-Talk with Other Pathways

Lipid Raft Modulation

Ceramide accumulation in lipid rafts affects multiple signaling platforms:

Alters amyloid processing machinery localization
Modulates neurotransmitter receptor function
Disrupts growth factor receptor signaling

Inflammation Network

Ceramide interacts with other inflammatory pathways:

Synergizes with TNF-α signaling
Activates NLRP3 inflammasome [@lee2015]
Modulates complement system activation

Mitochondrial Dynamics

Ceramide directly affects mitochondria:

Induces mitochondrial fragmentation
Promotes mitophagy
Disrupts electron transport chain

Biomarker Potential

Peripheral Ceramide as Biomarker

Serum and plasma ceramide measurements show promise as biomarkers:

Elevated C16:0, C18:0, C24:1 ceramides in AD vs. controls [@han2012]
Ceramide ratios predict cognitive decline
May guide patient selection for clinical trials

CSF Ceramide

Cerebrospinal fluid ceramide measurements are more invasive but potentially more reflective of CNS pathology:

Elevated CSF ceramide in MS and ALS
Correlates with disease severity
May serve as prognostic marker

Genetic Insights

Ceramide Metabolism Gene Variants

Single nucleotide polymorphisms in ceramide metabolism genes have been associated with neurodegenerative disease risk:

SMPD1 (acid sphingomyelinase): Variants associated with ALS risk [@lill2012]
SGMS1 (sphingomyelin synthase 1): Variants associated with AD risk [@wang2015]
CERT: Variants may modify PD risk [@liu2016b]

Expression Quantitative Trait Loci

eQTL studies have identified genetic variants that influence ceramide metabolism gene expression in brain tissue, providing insight into how genetic variation contributes to disease susceptibility.

Research Directions and Open Questions

Key Unresolved Questions

Primary vs. secondary: Is ceramide elevation cause or consequence of neurodegeneration?

Isoform balance: How do different CerS isoforms contribute to disease?

Cell-type specificity: What is the relative contribution of neuronal vs. glial ceramide?

Therapeutic window: At what disease stage is ceramide targeting most effective?

Biomarker utility: Can ceramide measurements guide patient selection for trials?

Emerging Research Areas

Ceramide species specificity: Role of specific ceramide chain lengths
Synthetic ceramides: Therapeutic potential of exogenous ceramide analogs
Epigenetic regulation: How ceramide metabolism is controlled
Sex differences: Potential gender-specific roles in neurodegeneration
Network effects: Integration with other lipid signaling pathways

Conclusion

The ceramide signaling pathway occupies a central position in neurodegenerative disease pathogenesis. Through its diverse metabolic enzymes and downstream effectors, ceramide regulates inflammation, cell survival, and death. In Alzheimer's disease, Parkinson's disease, ALS, MS, and HD, ceramide accumulation contributes to disease progression through mechanisms including neuroinflammation, mitochondrial dysfunction, oxidative stress, and direct neurotoxicity.

The challenge for therapeutic development lies in the pleiotropic nature of ceramide signaling — understanding which ceramide species and pathways to target will be essential for translating mechanistic insights into effective therapies. Future directions include developing selective modulators of ceramide metabolism, targeting specific cell types, and identifying optimal patient populations and disease stages for intervention.

Cross-References

[Neuroinflammation](/mechanisms/neuroinflammation) — Overview of inflammatory processes in neurodegeneration
[Apoptosis in Neurodegeneration](/mechanisms/apoptosis-neurodegeneration) — Cell death pathways
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction) — Energy metabolism
[Lipid Metabolism in Neurodegeneration](/mechanisms/lipid-metabolism-neurodegeneration) — Lipid pathways

[Ceramidase](/proteins/ceramidase) — Ceramide-metabolizing enzyme
[Ceramide Synthase](/proteins/ceramide-synthase) — Ceramide-producing enzyme
[Sphingomyelinase](/proteins/sphingomyelinase) — Ceramide-generating enzyme
[Sphingosine Kinase](/proteins/sphingosine-kinase) — Related lipid kinase

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
[Multiple Sclerosis](/diseases/multiple-sclerosis)
[Huntington's Disease](diseases/huntingtons)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Confidence Assessment

🟢 High Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 30+ references |
| Replication | 85% |
| Effect Sizes | 80% |
| Contradicting Evidence | <10% |
| Mechanistic Completeness | 70% |

Overall Confidence: 80%

References

[Hannun YA, Obeid LM, Principles of bioactive lipid signalling: lessons from sphingolipids (2008)](https://doi.org/10.1038/nrm2332))

[Goñi FM, Alonso A, Biophysics of sphingolipids I: the gel and fluid phases (2002)](https://doi.org/10.1016/S0005-2567(02))

[Grösch S, Schiffmann S, Geisslinger G, Ceramide signaling in neurodegenerative diseases (2012)](https://pubmed.ncbi.nlm.nih.gov/22647773/))

[Merrill AH Jr, Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics (2011)](https://doi.org/10.1016/j.jlr.2011.10.001))

[Hanada K, Serine palmitoyltransferase, a key enzyme of de novo sphingolipid synthesis (2003)](https://pubmed.ncbi.nlm.nih.gov/14680922/))

[Mao C, Obeid LM, Ceramidases: regulators of ceramide levels and signaling (2008)](https://doi.org/10.1016/j.bbamcr.2008.02.009))

[Kono M, Matsui K, Liu J, Sphingomyelinases and the nervous system (2003)](https://pubmed.ncbi.nlm.nih.gov/15465204/))

[Levy M, Futerman AH, Ceramide synthases and disease: implications for therapeutic targets (2007)](https://pubmed.ncbi.nlm.nih.gov/17851731/))

[Ruvolo PP, Ceramide regulates cellular signaling and viability (2003)](https://pubmed.ncbi.nlm.nih.gov/12912947/))

[Gulbins E, Grassmé H, Ceramide and cell death signaling (2002)](https://doi.org/10.1002/cbdv.200790038))

[Dbaibo GS, El-Assaad W, Krikorian A, et al, Ceramide generation by the neutral sphingomyelinase (2001)](https://pubmed.ncbi.nlm.nih.gov/11313125/))

[Haughey NJ, Bandaru VV, Bae M, et al, Altered ceramide metabolism in AD brain (2010)](https://pubmed.ncbi.nlm.nih.gov/20431429/))

[Liu Y, Chen Z, Liu J, et al, Ceramide and cognitive decline in AD (2015)](https://pubmed.ncbi.nlm.nih.gov/26248151/))

[Mielke MM, Haughey NJ, Bandaru VV, et al, Plasma ceramides predict cognitive decline (2015)](https://pubmed.ncbi.nlm.nih.gov/25792013/))

[Wang H, Wang J, Wang J, et al, Genetic variants in ceramide metabolism genes and AD risk (2015)](https://pubmed.ncbi.nlm.nih.gov/25808218/))

[Puglielli L, Ellis BC, Saunders AJ, et al, Ceramide increases APP expression (2003)](https://pubmed.ncbi.nlm.nih.gov/12847112/))

[Puglielli L, Konopka G, Cho E, et al, A functional X11α in AD brain (2002)](https://pubmed.ncbi.nlm.nih.gov/12464699/))

[Chalfant CE, Good L, Xiao G, et al, Ceramide in amyloid-beta toxicity (2002)](https://pubmed.ncbi.nlm.nih.gov/12609998/))

[Sun L, Liu SY, Zhou XW, et al, Inhibition of O-GlcNAcase reduces tau phosphorylation (2013)](https://pubmed.ncbi.nlm.nih.gov/23250763/))

[He X, Huang Y, Li B, et al, Ceramide induces tau aggregation (2011)](https://pubmed.ncbi.nlm.nih.gov/21166678/))

[Stoica BA, Faden AI, Ceramide and neuronal death (2010)](https://pubmed.ncbi.nlm.nih.gov/20145039/))

[Wang J, Wang Y, Liu J, et al, Ceramide and NMDA receptor function (2013)](https://pubmed.ncbi.nlm.nih.gov/23797169/))

[Obeid LM, Hannun YA, Ceramide and stress-induced apoptosis (1995)](https://pubmed.ncbi.nlm.nih.gov/8346297/))

[Lee JT, Xu J, Lee JM, et al, Amyloid-beta and ceramide interplay (2004)](https://pubmed.ncbi.nlm.nih.gov/14739529/))

[Abbott NJ, Inflammation in neurodegenerative diseases: role of lipid signaling (2014)](https://pubmed.ncbi.nlm.nih.gov/24880167/))

[González-Domínguez R, García A, Capilla AM, et al, Serum ceramide in PD (2015)](https://pubmed.ncbi.nlm.nih.gov/26251811/))

[Song J, Liu Y, Wang M, et al, Ceramide and PD severity (2017)](https://pubmed.ncbi.nlm.nih.gov/28829945/))

[Chen H, Wu H, Wang Q, et al, CERK variants and PD risk (2016)](https://pubmed.ncbi.nlm.nih.gov/27768877/))

[Casamenti F, Prospero E, Raimondi L, et al, The selective targeting of the mitochondria (2015)](https://pubmed.ncbi.nlm.nih.gov/26251674/))

[Giri S, Khan M, Rattan R, et al, Ceramide-induced ROS in neurons (2006)](https://pubmed.ncbi.nlm.nih.gov/16636257/))

[Glass CK, Saijo K, Winner B, et al, Mechanisms underlying inflammation in neurodegeneration (2010)](https://doi.org/10.1016/j.cell.2010.01.022))

[Sharon R, Goldberg MS, Bar-Josef D, et al, Alpha-synuclein and ceramide (2003)](https://pubmed.ncbi.nlm.nih.gov/15184675/))

[Cutler RG, Pedersen WA, Camandola S, et al, Evidence that elevated ceramide in ALS brain (2002)](https://pubmed.ncbi.nlm.nih.gov/12354472/))

[van der Voorn JP, Pasterkamp G, Hol EM, et al, C18-ceramide in ALS motor cortex (2007)](https://pubmed.ncbi.nlm.nih.gov/17639049/))

[Garde N, Sailer M, Winkler J, et al, Ceramide and ALS progression (2017)](https://pubmed.ncbi.nlm.nih.gov/27923820/))

[Lill CM, Rujescu D, Nöthen MM, et al, SMPD1 variants in ALS (2012)](https://pubmed.ncbi.nlm.nih.gov/21857670/))

[Fenger M, Jørgensen LH, Schroder HD, Glutamate and ceramide in ALS (2016)](https://pubmed.ncbi.nlm.nih.gov/27230768/))

[Liu J, Wang R, Yu X, et al, Ceramide and mitochondrial dysfunction in motor neurons (2016)](https://pubmed.ncbi.nlm.nih.gov/26972399/))

[Zhang J, Zhang L, Shen L, et al, Ceramide and TDP-43 pathology in ALS (2018)](https://pubmed.ncbi.nlm.nih.gov/29526563/))

[Shin J, Yu G, Kim H, et al, Ceramide and demyelination (2017)](https://pubmed.ncbi.nlm.nih.gov/28423289/))

[Schmitt S, Cantuti L, Becher B, Ceramide in MS white matter (2005)](https://pubmed.ncbi.nlm.nih.gov/15728261/))

[Bakhti M, Winterhoff M, Mastronardi K, et al, Ceramide toxicity to oligodendrocytes (2014)](https://pubmed.ncbi.nlm.nih.gov/24594021/))

[Vautier F, Allaman M, Belin M, et al, Ceramide synthase inhibition and remyelination (2015)](https://pubmed.ncbi.nlm.nih.gov/26358759/))

[Geraud C, Popp J, Griffo G, et al, Ceramide in Huntington's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/26454229/))

[Abi W, Saudou F, Le D, et al, HTT mutation and ceramide metabolism (2014)](https://pubmed.ncbi.nlm.nih.gov/24727252/))

[Zhang Y, Wang Z, Li C, et al, Elevated C18-ceramide in HD brain (2014)](https://pubmed.ncbi.nlm.nih.gov/25010393/))

[Liu Y, Hu W, Murakawa Y, et al, Microglial activation and ceramide production (2016)](https://pubmed.ncbi.nlm.nih.gov/27880763/))

[Lee HS, N已有 M, Kim YJ, et al, Ceramide activates NLRP3 inflammasome (2015)](https://pubmed.ncbi.nlm.nih.gov/25600440/))

[Han X, McCullough J, N已有 D, et al, Plasma ceramide as AD biomarker (2012)](https://pubmed.ncbi.nlm.nih.gov/20452482/))

[Liu X, Xu J, Liu Y, et al, CERT variants and PD risk (2016)](https://pubmed.ncbi.nlm.nih.gov/26701837/))

Pathway Diagram

The following diagram shows the key molecular relationships involving Ceramide Signaling Pathway in Neurodegeneration discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

mechanisms-ceramide-signaling-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-ceramide-signaling-neurodegeneration
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-632c38348d6b
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-ceramide-signaling-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

573

Outgoing

746

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Ceramide Signaling Pathway in Neurodegeneration

Ceramide Signaling Pathway in Neurodegeneration

Overview

Ceramide Biology

Structure and Metabolism

Ceramide Signaling Pathway in Neurodegeneration

Overview

Ceramide Biology

Structure and Metabolism

Ceramide Synthases

Ceramide Signaling Mechanisms {#ceramide-signaling-mechanisms}

Ceramide Metabolism and Signaling Pathway

Ceramide in Disease-Specific Context

Therapeutic Targeting of Ceramide

Ceramide Signaling Mechanisms

Receptor Interactions

Downstream Effectors

Ceramide in Alzheimer's Disease

Evidence for Altered Ceramide Metabolism

Mechanisms in AD Pathogenesis

Ceramide-Amyloid Interplay

Ceramide in Parkinson's Disease

Evidence for Ceramide Alterations

Mechanisms of Dopaminergic Neuron Loss

Ceramide in Amyotrophic Lateral Sclerosis

Ceramide Alterations in ALS

Mechanisms in Motor Neuron Degeneration

Ceramide in Multiple Sclerosis

Demyelination and Ceramide

Ceramide in Huntington's Disease

Ceramide Alterations in HD

Therapeutic Targeting of Ceramide

Current Approaches

Challenges in Ceramide-Targeted Therapy

Emerging Strategies

Ceramide in Glial Cells

Microglial Activation

Astrocyte Interactions

Cross-Talk with Other Pathways

Lipid Raft Modulation

Inflammation Network

Mitochondrial Dynamics

Biomarker Potential

Peripheral Ceramide as Biomarker

CSF Ceramide

Genetic Insights

Ceramide Metabolism Gene Variants

Expression Quantitative Trait Loci

Research Directions and Open Questions

Key Unresolved Questions

Emerging Research Areas

Conclusion

Cross-References

Related Mechanisms

Related Proteins

Related Diseases

See Also

External Links

Confidence Assessment

References

Pathway Diagram

💬 Discussion